HIGHLIGHTS
SUMMARY
After one month following EVAR implantations, CTA was carried out to evidence a possible endoleak occurrence, and, on the basis of this evaluation, patients were stratified in two different cohorts: "Endoleak" and "No Endoleak". The concentrations of all analyzed EV subpopulations were then compared between the two cohorts of patients. Dots represent size (cm) of aneurysms in patients developing endoleaks (n=6) (A), and in16 patients who did not develop endoleaks (n=12) (B). Of note, patients presenting higher levels of CD31+ CD62P+ EVs (above 9.8 EVs/µL) one month after EVAR implantation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.